Predix Pharmaceuticals has initiated a Phase I clinical trial in healthy volunteers to study the safety, tolerability, and pharmacokinetics of PRX-07034, which is being developed for the treatment of obesity and cognitive impairment.

PRX-07034 is the fourth novel drug candidate from Preix's drug discovery platform to progress into human clinical trials. It is a novel, highly selective, small-molecule antagonist of a specific G-protein coupled receptor known as 5-HT6. PRX-07034 has shown cognitive-enhancing properties in preclinical animal models of memory impairment, as well as significant reductions of both food intake and body weight in several preclinical animal models of obesity.